PDL Biopharma (PDLI) 8-K PDL BioPharma Provides Second Quarter 2012 Royalty Revenue Guidance of $125 Million

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *
Avastin	Q1	Q2	Q3	Q4	Total
2012	23,215	41,670	-	-	64,886
2011	22,283	41,967	23,870	22,886	111,006
2010	16,870	44,765	29,989	24,922	116,547
2009	13,605	35,161	21,060	15,141	84,966
2008	9,957	30,480	19,574	12,394	72,405
2007	8,990	21,842	17,478	9,549	57,859
2006	10,438	15,572	15,405	12,536	53,952
Herceptin	Q1	Q2	Q3	Q4	Total
2012	25,702	44,628	-	-	70,330
2011	25,089	42,209	31,933	21,812	121,042
2010	23,402	38,555	27,952	25,441	115,350
2009	16,003	32,331	26,830	18,615	93,779
2008	14,092	34,383	28,122	20,282	96,880
2007	19,035	28,188	22,582	14,802	84,608
2006	15,142	19,716	21,557	20,354	76,769
Lucentis	Q1	Q2	Q3	Q4	Total
2012	10,791	27,938	-	-	38,728
2011	8,878	24,313	12,157	10,750	56,099
2010	7,220	19,091	10,841	8,047	45,198
2009	4,621	12,863	8,123	6,152	31,759
2008	3,636	11,060	7,631	4,549	26,876
2007	2,931	6,543	6,579	3,517	19,570
2006	-	-	289	3,335	3,624
Xolair	Q1	Q2	Q3	Q4	Total
2012	5,447	8,609	-	-	14,056
2011	4,590	7,621	5,916	5,823	23,949
2010	3,723	6,386	4,980	4,652	19,741
2009	2,665	5,082	4,085	3,722	15,553
2008	1,488	4,866	3,569	2,927	12,850
2007	1,684	3,942	3,332	2,184	11,142
2006	2,263	2,969	3,041	2,495	10,768
Tysabri	Q1	Q2	Q3	Q4	Total
2012	11,233	12,202	-	-	23,435
2011	9,891	10,796	11,588	11,450	43,725
2010	8,791	8,788	8,735	9,440	35,754
2009	6,656	7,050	7,642	8,564	29,912
2008	3,883	5,042	5,949	6,992	21,866
2007	839	1,611	2,084	2,836	7,370
2006	-	-	-	237	237
Actemra	Q1	Q2	Q3	Q4	Total
2012	1,705	2,074	-	-	3,778
2011	913	1,136	1,401	1,460	4,910
2010	1,587	237	315	688	2,827
2009	585	537	909	1,197	3,228
2008	44	-	146	369	559
2007	32	-	-	17	49
2006	-	-	-	-	-
* As reported to PDL by its licensees
Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *
Avastin	Q1	Q2	Q3	Q4	Total
2012	1,502,757	1,573,727	-	-	3,076,484
2011	1,597,461	1,582,705	1,581,095	1,469,994	6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218	6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053	5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382	4,485,454
2007	678,068	746,587	797,013	875,084	3,096,752
2006	439,318	516,052	570,551	592,897	2,118,817
Herceptin	Q1	Q2	Q3	Q4	Total
2012	1,515,255	1,625,313	-	-	3,140,569
2011	1,391,568	1,559,975	1,642,898	1,432,771	6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310	5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626	4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806	4,699,428
2007	891,761	949,556	979,602	1,015,033	3,835,952
2006	529,585	659,719	761,099	803,576	2,753,979
Lucentis	Q1	Q2	Q3	Q4	Total
2012	1,079,092	1,086,543	-	-	2,165,635
2011	887,757	943,418	1,052,809	1,075,015	3,958,999
2010	721,967	698,890	745,376	804,684	2,970,917
2009	462,103	469,736	555,296	615,212	2,102,347
2008	363,615	393,682	460,167	454,922	1,672,386
2007	224,820	219,579	299,995	322,300	1,066,695
2006	-	-	10,689	157,742	168,431
Xolair	Q1	Q2	Q3	Q4	Total
2012	310,234	314,638	-	-	624,873
2011	267,754	277,642	310,874	314,911	1,171,182
2010	228,859	225,878	251,055	263,389	969,179
2009	184,669	181,086	211,006	219,693	796,454
2008	137,875	169,521	177,179	183,753	668,329
2007	129,172	130,700	144,250	147,754	551,876
2006	95,241	99,354	112,608	118,002	425,204
Tysabri	Q1	Q2	Q3	Q4	Total
2012	374,430	401,743	-	-	776,173
2011	329,696	356,876	388,758	381,618	1,456,948
2010	293,047	287,925	293,664	316,657	1,191,292
2009	221,854	229,993	257,240	285,481	994,569
2008	129,430	163,076	200,783	233,070	726,359
2007	30,468	48,715	71,972	94,521	245,675
2006	-	-	-	7,890	7,890
Actemra	Q1	Q2	Q3	Q4	Total
2012	56,662	66,624	-	-	123,286
2011	30,433	35,370	46,709	48,671	161,183
2010	52,908	5,405	10,493	22,919	91,725
2009	19,504	17,920	30,313	39,888	107,625
2008	1,452	1,377	5,981	12,305	21,115
2007	-	-	-	1,137	1,137
2006	-	-	-	-	-
* As reported to PDL by its licensees
Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
Avastin Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	708,539	719,967	688,966	684,878	652,824	724,483
US Made & ex-US Sold	580,981	548,710	587,975	375,830	448,037	532,979
ex-US Made & Sold	307,941	314,028	304,155	409,286	401,896	316,265
Total	1,597,461	1,582,705	1,581,095	1,469,994	1,502,757	1,573,727
US Made & Sold	44%	45%	44%	47%	43%	46%
US Made & ex-US Sold	36%	35%	37%	26%	30%	34%
ex-US Made & Sold	19%	20%	19%	28%	27%	20%
Herceptin Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	409,854	442,903	445,395	453,168	456,920	497,109
US Made & ex-US Sold	423,053	642,670	495,086	612,908	523,353	466,477
ex-US Made & Sold	558,661	474,402	702,416	366,695	534,982	661,727
Total	1,391,568	1,559,975	1,642,898	1,432,771	1,515,255	1,625,313
US Made & Sold	29%	28%	27%	32%	30%	31%
US Made & ex-US Sold	30%	41%	30%	43%	35%	29%
ex-US Made & Sold	40%	30%	43%	26%	35%	41%
Lucentis Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	378,451	409,674	422,335	428,884	433,428	412,131
US Made & ex-US Sold	509,307	533,745	630,474	646,131	645,665	674,411
ex-US Made & Sold	-	-	-	-	-	-
Total	887,757	943,418	1,052,809	1,075,015	1,079,092	1,086,543
US Made & Sold	43%	43%	40%	40%	40%	38%
US Made & ex-US Sold	57%	57%	60%	60%	60%	62%
ex-US Made & Sold	0%	0%	0%	0%	0%	0%
Xolair Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	164,621	167,608	184,837	188,728	185,505	193,600
US Made & ex-US Sold	-	-	-	-	-	-
ex-US Made & Sold	103,133	110,034	126,037	126,184	124,729	121,039
Total	267,754	277,642	310,874	314,911	310,234	314,638
US Made & Sold	61%	60%	59%	60%	60%	62%
US Made & ex-US Sold	0%	0%	0%	0%	0%	0%
ex-US Made & Sold	39%	40%	41%	40%	40%	38%
Total Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	1,661,465	1,740,152	1,741,534	1,755,657	1,728,678	1,827,323
US Made & ex-US Sold	1,513,340	1,725,125	1,713,535	1,634,869	1,617,054	1,673,867
ex-US Made & Sold	969,735	898,464	1,132,608	902,165	1,061,607	1,099,031
Total	4,144,540	4,363,741	4,587,677	4,292,691	4,407,339	4,600,221
US Made & Sold	40%	40%	38%	41%	39%	40%
US Made & ex-US Sold	37%	40%	37%	38%	37%	36%
ex-US Made & Sold	23%	21%	25%	21%	24%	24%
* As reported to PDL by its licensees
Totals may not sum due to rounding